Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes. (OXOART2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05076032
Recruitment Status : Recruiting
First Posted : October 13, 2021
Last Update Posted : October 13, 2021
Sponsor:
Information provided by (Responsible Party):
OXOLIFE

Brief Summary:
The main objective of this clinical research trial is to test the efficacy of OXO-001 in a daily oral administration increasing the pregnancy rate in IVF/ICSI by preparing the uterus to receive the embryo.

Condition or disease Intervention/treatment Phase
Infertility, Female Infertility Drug: OXO-001 Drug: Placebo Phase 2

Detailed Description:

Assisted reproductive techniques are the most common procedures to fulfill the desire for pregnancy in infertile women. Unfortunately, more than half of the assisted reproduction cycles result in implantation failure or early pregnancy loss, the two main causes of infertility and the most important unmet medical need in the field of infertility with current treatments.

This clinical trial aims to test the capacity of OXO-001 to enhance embryo implantation. It is a phase II, randomised, double-blind, parallel-group, placebo-controlled trial that will assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 351 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial to Assess Ongoing Pregnancy Rate With OXO-001 (200/300 mg) or Placebo at 10 Weeks Following Fresh Single Blastocyst Transfer From Donor Oocyte IVF/ICSI
Actual Study Start Date : September 1, 2021
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : November 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

Arm Intervention/treatment
Experimental: OXO-001 200 mg
Two tablets of 100 mg have to be taken once daily in the early morning.
Drug: OXO-001
OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.

Experimental: OXO-001 300 mg
Two tablets of 150 mg have to be taken once daily in the early morning.
Drug: OXO-001
OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.

Placebo Comparator: Placebo
Two tablets have to be taken once daily in the early morning.
Drug: Placebo
Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.




Primary Outcome Measures :
  1. Ongoing pregnancy rate [ Time Frame: 10 weeks post Embryo Transfer (ET) ]
    Rate of subjects with uterine pregnancy and a foetal heartbeat confirmed by ultrasound (US)


Secondary Outcome Measures :
  1. Positive blood pregnancy test [ Time Frame: 10 to 15 days post ET ]
    Percentage of women with positive blood pregnancy test

  2. Vital pregnancy at 6 weeks [ Time Frame: 6 weeks post ET ]
    Intra-uterine pregnancy with foetal heartbeat at 6 weeks post ET

  3. Early pregnancy loss rate [ Time Frame: 10 weeks post ET ]
    Early pregnancy loss rate within 10 weeks of gestation (i.e. after positive blood pregnancy test 10-15 days post ET).

  4. Adverse events [ Time Frame: From the first intake of the investigational product until 10 weeks post ET ]
    Incidence and severity of adverse events/serious adverse events

  5. Hematology and biochemistry values [ Time Frame: From the first intake of the investigational product until 10 weeks post ET ]
    Changes from baseline in haematology and biochemistry values

  6. Vital signs [ Time Frame: From the first intake of the investigational product until 10 weeks post ET ]
    Changes from baseline in heart rate (bpm)

  7. Vital signs [ Time Frame: From the first intake of the investigational product until 10 weeks post ET ]
    Changes from baseline blood pressure mmHg



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Voluntary informed consent.
  • Infertile female subjects indicated for egg donor programme in the context of ART.
  • Subjects aged ≥ 18 to ≤ 45 years at screening.
  • Body mass index (BMI) ≥ 18.0 and < 30.0 kg/m2.
  • Normal results of a 2-dimensional (2D) or 3-dimensional (3D) transvaginal US (TVUS) at screening.
  • Planned transfer of a fresh single blastocyst from a donated egg.
  • Good quality sperm.
  • Planned endometrial preparation and luteal support.

Exclusion Criteria:

  • History of two or more failed in-vitro fertilisation (IVF) / intra-cytoplasmic sperm injection (ICSI) cycles after embryo transfer of donor oocyte during the last attempts prior to the trial.
  • Gynaecological abnormality relevant to the ART procedure and outcome, which in the opinion of the investigator could interfere with the trial objectives.
  • Abnormal haemorrhage of the reproductive tract of undetermined origin.
  • Endometrial biopsy or endometrial local injury within one month prior to screening.
  • Diagnosis of severe endometriosis and/or adenomyosis.
  • Positive hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus results.
  • Relevant clinically significant abnormality in the results of safety laboratory tests at screening.
  • Systemic disease which might interfere with the purpose of the trial.
  • Any malignant neoplasm.
  • Known history of venous thrombosis or thromboembolism, including any coagulation abnormality leading to an increased risk of clotting.
  • History of uncontrolled hypertension.
  • Known hypersensitivity to any component of the IP used in this trial.
  • Known allergy, hypersensitivity or any other contraindications to preparations used in the context of endometrial preparation and fresh ET with a donated egg.
  • History (within 12 months) of or known current problems with alcohol or substance abuse.
  • Any condition or treatment that, in the opinion of the investigator, may jeopardise the trial conduct according to the protocol.
  • Previous treatment with the IP of this trial at any time or participation in another clinical trial within the past 3 months prior to screening.
  • Employees of the investigator or trial centre, with direct involvement in the proposed trial or other studies under the direction of that investigator or trial centre, as well as family members of the employees or the principal investigator.
  • Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05076032


Locations
Show Show 24 study locations
Sponsors and Collaborators
OXOLIFE
Layout table for additonal information
Responsible Party: OXOLIFE
ClinicalTrials.gov Identifier: NCT05076032    
Other Study ID Numbers: OXO-001-201
2021-000001-25 ( EudraCT Number )
First Posted: October 13, 2021    Key Record Dates
Last Update Posted: October 13, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by OXOLIFE:
Endometrial receptivity
Embryo implantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility
Infertility, Female